Interview with Derek Williams, Vice President and General Manager, Vifor Pharma…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
Address: The Old Stables, Bagshot Park, Bagshot, Surrey GU19 5PJ, United Kingdom
Tel: +44 (0) 1276 853 600
Web: http://www.viforpharma.com/en/
Vifor Pharma UK is an affiliate of the Vifor Pharma, the pharma business sector of the Galenica Group. Vifor Pharma, the Pharma business sector of the Galenica Group, is an internationally active company, which researches, develops, manufactures and markets pharmaceutical products worldwide. Galenica is a diversified group active throughout the healthcare market which among other things, develops manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks.
Vifor Pharma UK focuses its activities on iron deficiency anaemia, a globally widespread ailment. It develops and manufactures iron replacement pharmaceutical products. These products are:
• Ferinject
• Venofer
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
